Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Astex up on data for second-generation Dacogen

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) added $1.34 (24%) to $6.82 on Wednesday after reporting that subcutaneous once-daily SGI-110 led to an overall

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE